Eptifibatide and ST Segment Resolution Following Primary PCI

Myocardial Infarction Clinical Trial

— ESTEEM  

Official title:

Eptifibatide and ST Segment Resolution Following Primary PCI

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00812435
• Other study ID #: ESTEEM
• Status: Terminated
• Phase: Phase 3
• First received: February 17, 2008
• Last updated: August 8, 2014
• Start date: August 2007
• Est. completion date: March 2011

Study information

• Verified date: August 2014
• Source: Medstar Research Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This is a prospective, open label, randomized trial of 100 patients who present to the cardiac catheterization laboratory with an ST Elevation Myocardial Infarction for primary PCI. Patients may receive up-front unfractionated heparin or low molecular weight heparin, but not glycoprotein IIb/IIIa inhibitors or thrombolytics. Patients will be consented prior to the diagnostic catheterization and will be randomized once the patient is deemed amenable to PCI to receive eptifibatide or no eptifibatide just prior to or at the time of primary angioplasty. Patients will be randomized in a 1:1 fashion. All patients will be assessed for the primary endpoint of ST resolution at 60 minutes post PCI and followed throughout the duration of the hospitalization and up to 30 days for secondary endpoint evaluation.

Description:

The aim of this study is to evaluate the effectiveness and safety of adjunctive eptifibatide during primary PCI in patients presenting to the catheterization laboratory within 12 hours of symptom onset. The primary objective of this randomized clinical trial is to examine the safety and effectiveness of the addition of eptifibatide therapy immediately prior to or at the time of PCI in patients presenting with a STEMI for primary PCI who have not received up-front glycoprotein IIb/IIIa inhibitor therapy. The secondary objective of this clinical trial is to assess effectiveness of adjunct eptifibatide therapy with respect to the following endpoints:

• Complete ST resolution (defined above) at 90 and 180 minutes post primary PCI

• TIMI flow at the end of the PCI (as reported by the investigator at the end of the procedure)

• MACE evaluation at discharge and 30 days post PCI (MACE defined as: death, reinfarction, and need for urgent ischemia-driven target vessel revascularization)

• Stent thrombosis at discharge and 30 days

• Major Bleed (Major Bleed defined as: TIMI Major Bleeding)

• Minor Bleed (Minor Bleed defined as: TIMI Minor Bleeding)

• ST segment resolution at 60, 90 and 180 minutes based on the additional measure in the Schroder's Index:

• Partial resolution defined as 30-70% ST-segment resolution, and

• No resolution defined as <30% ST-segment resolution.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 22
• Est. completion date: March 2011
• Est. primary completion date: July 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients >18 years old

• Patients with acute myocardial infarction whose symptom onset is within 12 hours of presentation

• ST-segment elevation 1 mm in 2 contiguous limb leads or 2 mm in 2 contiguous precordial leads

• Patients eligible for PCI

• Target lesion(s) in a native vessel

• Target lesion stenosis >50% by angiography (visual estimate)

• Patients who are amenable to participating in study procedures and follow-up

• Patient or legal guardian has been informed and agrees to provide approved written informed consent and data privacy authorization

Exclusion Criteria:

• Patients with cardiogenic shock (SBP<80 mmHg for >30 minutes or requiring pressors or IABP due to hypotension)

• Patients with cardiac arrest at any point prior to intervention (within the preceeding 24 hours)

• Patients on chronic warfarin (Coumadin) therapy

• Patients with known bleeding diathesis or active bleeding at the time of presentation to the catheterization laboratory

• Patients with known bleeding diathesis or active bleeding within prior 3 months

• Patients who receive thrombolytic therapy or glycoprotein IIb/IIIa inhibitors prior to PCI (within the preceding 8 hours)

• Patients with a platelet count <100,000 cells/mm3 within the preceeding 7 days

• Patients with known allergies to aspirin, clopidogrel bisulfate (Plavix), heparin, bivalirudin, glycoprotein IIb/IIIa inhibitors or intravenous contrast dye that cannot be medically managed

• Patients with major surgery within the past 6 months or scheduled surgery within 6 weeks

• Patients with significant unprotected left main disease (stenosis >60%) or with multivessel coronary disease that will require emergent coronary artery bypass surgery

• Patients with TIA or CVA within the past 30 days or any history of hemorrhagic stroke

• Patients who have undergone PCI within the preceding 30 days prior to enrollment

• Patients with known impaired renal function

• Patient is know to be pregnant or lactating

• Patients with active participation in another device or drug study

• Patients with comorbidities conferring a life expectancy of less than a year

• Patients with left bundle branch block

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction

Intervention

Drug:
• eptifibitide
Patients will be randomized to eptifibatide or no eptifibatide. If randomized to eptifibatide: 180 mcg/kg Bolus; 2 mcg/kg/min infusion immediately prior to primary PCI or at the time of PCI and for 18 - 24 hours following the PCI Second 180 mcg/kg Bolus 10 min after the first

Locations

Country	Name	City	State
United States	Washington Hospital Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Medstar Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint will be complete ST resolution 60 minutes following primary PCI where complete ST resolution is defined as =70% ST resolution compared to the qualifying ECG.		In patient hopsitalization	Yes
Secondary	Complete ST resolution (defined above) at 90 and 180 minutes following primary PCI; TIMI flow at the end of the PCI; and MACE evaluation at discharge and 30 days post PCI		In-patient hospitalization and 30 days post discharge	Yes